Author

Stephen Lake

Institution: Alexion Pharmaceuticals (United States)

Observed institution: Alexion Pharmaceuticals (United States)

OpenAlex ID: A5148732694

Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials

2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 2

Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials

2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 1

PA-349 Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis

2026 · Julia Catini, Ashu Wechalekar, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis

2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia

ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis

2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia

MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis

2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia

Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.

2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology

Works count: 7

Citation count: 3

H-index: 1

I10-index: